Pinto JV, et al. - Via performing this meta-analysis, researchers investigated the efficacy and tolerability of cariprazine in the treatment of bipolar disorder (BD). They analyzed seven studies and identified an association of cariprazine with a moderate and significant reduction of manic symptoms based on the Young Mania Rating Scale change scores. Relative to placebo, cariprazine was related to significantly higher remission and response rates for manic and mixed episodes. Findings support cariprazine as safe and efficacious for treating acute mania and mixed episodes associated with BD. They suggest cariprazine at doses of 1.5-3 mg/day as effective in acute bipolar depression but with small effect sizes.